PDCD1 and cancer: Recently, a meta-analysis demonstrated that ICIs were positively associated with higher levels of QoL and longer time to deterioration in cancer patients, which was consistent with our results, but the study incorporated a variety of cancer types and was not specific to PD-1/PD-L1 inhibitors, thus was not as homogenous as our study [29].